ArticleMolecular medicine reports2015
Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma.
Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pooled it
- Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review.Chinese journal of cancer · 2017Pooled it
- Prognostic Value of Podoplanin in Various Tumors.Technology in cancer research & treatmentPooled it
- Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.Matrix biology : journal of the International Society for Matrix Biology · 2025Review
- Integrative bioinformatics and experimental analyses identify U2SURP as a novel lactylation-related prognostic signature in esophageal carcinoma.Immunologic research · 2025Article
- Therapeutic Apheresis Using a β2-Microglobulin Removal Column Reduces Circulating Tumor Cell Count.Journal of personalized medicine · 2024Article
- Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.Antibodies (Basel, Switzerland) · 2022Article
- Platelets involved tumor cell EMT during circulation: communications and interventions.Cell communication and signaling : CCS · 2022Review
- Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.International journal of molecular sciences · 2022Article
- Review
- Vimentin immunoexpression and its prognostic activity in colon cancer among Caucasian patients.Przeglad gastroenterologiczny · 2022Article
- TPM3 mediates epithelial-mesenchymal transition in esophageal cancer via MMP2/MMP9.Annals of translational medicine · 2021Article
- Targeting MUC1-C reverses the cisplatin resistance of esophageal squamous cell carcinomaTranslational cancer research · 2021Article
- Matrine suppresses lung cancer metastasisAmerican journal of cancer research · 2021Article
- Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.World journal of gastroenterology · 2020Article
- Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma.Frontiers in oncology · 2020Article
- Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer.International journal of clinical and experimental pathology · 2020Article
- Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells.Cancer cell international · 2020Article
- A pull-down and slot blot-based screening system for inhibitor compounds of the podoplanin-CLEC-2 interaction.PloS one · 2019Article
- Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Podoplanin is a small membrane mucin, which is involved in cell migration and cancer cell invasion. However, the roles of podoplanin in esophageal squamous cell carcinoma (ESCC) are poorly understood. In the present study, 139 cases of surgically resected ESCC were analyzed and the clinicopathological significance of podoplanin membrane expression in ESCC was demonstrated. Podoplanin expression was positive in 66.2% (92/139) of ESCC samples; with weak expression in 32.4% (45/139), and strong expression in 33.8% (47/139). Membrane expression of podoplanin was significantly associated with tumor status (P=0.001), venous invasion (P=0.035) and Union for International Cancer Control stage (P=0.029). Patients who exhibited strong podoplanin expression, were shown to have a poorer prognosis [hazard ratio (HR), 3.949; 95% confidence interval (CI), 2.001‑7.794]. Expression of vimentin, a mesenchymal marker, was detected in 49 cases (35.3%) and was associated with venous invasion (P=0.020). Vimentin‑positive cases were also more likely to have a worse prognosis than vimentin‑negative cases (HR, 2.161; 95% CI, 1.300‑3.592). Podoplanin membrane expression was significantly correlated with vimentin cytoplasmic expression in ESCC (P<0.001). The present study confirmed that podoplanin and vimentin are independent predictors of mortality (HR, 3.084; 95% CI, 1.543‑6.164). These results suggest that podoplanin membrane expression results in epithelial‑mesenchymal transition and promotes aggressive invasion in human ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.